cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ultragenyx Pharmaceutical Inc
3 own
8 watching
Current Price
$47.64
$1.7
(3.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,338.6M
52-Week High
52-Week High
85.53
52-Week Low
52-Week Low
33.36
Average Volume
Average Volume
0.74M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,338.6M
icon52-Week High85.53
icon52-Week Low33.36
iconAverage Volume0.74M
iconDividend Yield--
iconP/E Ratio--
What does the Ultragenyx Pharmaceutical Inc do?
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Children's Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
Read More
How much money does Ultragenyx Pharmaceutical Inc make?
News & Events about Ultragenyx Pharmaceutical Inc.
Zolmax
3 months ago
Ultragenyx Pharmaceutical (NASDAQ:RARE Get Rating) was upgraded by equities research analysts at Guggenheim from a neutral rating to a buy rating in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm presently has a $50.00 price target on the biopharmaceutical ...
Globe Newswire
5 months ago
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (Ultragenyx), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and ...
Ticker Report
5 months ago
Mirae Asset Global Investments Co. Ltd. trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) by 14.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The firm owned 136,906 shares of...
Zolmax
6 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) Equities researchers at SVB Leerink issued their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Thursday, July 28th. SVB Leerink analyst J. Schwartz expects that the biopharmaceutical ...
Ticker Report
6 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) Investment analysts at Wedbush reduced their FY2026 earnings estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Friday, July 29th. Wedbush analyst L. Chico now expects that the ...
Frequently Asked Questions
Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc share price today?
plus_minus_icon
Can Indians buy Ultragenyx Pharmaceutical Inc shares?
plus_minus_icon
How can I buy Ultragenyx Pharmaceutical Inc shares from India?
plus_minus_icon
Can Fractional shares of Ultragenyx Pharmaceutical Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ultragenyx Pharmaceutical Inc stocks?
plus_minus_icon
What is today’s traded volume of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What is today’s market capitalisation of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ultragenyx Pharmaceutical Inc?
plus_minus_icon
What percentage is Ultragenyx Pharmaceutical Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ultragenyx Pharmaceutical Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$47.64
$1.7
(3.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.97
$0.47 (1.16 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$31.82
$0.06 (0.19 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.64
$0.22 (0.64 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$120.79
$2.95 (2.50 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.97
$0.47 (1.16 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$31.82
$0.06 (0.19 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.64
$0.22 (0.64 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$120.79
$2.95 (2.50 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00